Galapagos NV (GLPG.AS)
| Previous close | 27.40 |
| Open | 27.38 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 27.38 - 28.28 |
| 52-week range | 26.30 - 41.92 |
| Volume | |
| Avg. volume | 90,791 |
| Market cap | 1.812B |
| Beta (5Y monthly) | 0.04 |
| PE ratio (TTM) | 58.51 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Galapagos creates new subscription right plans
Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries. On 16 May 2024, the Board of Directors of Galapagos approved “Subscription Right Plan 2024 BE”, intended for members of personnel of the company, “Subscription Right Plan 2024 RMV,” intend
- Globe Newswire
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.
BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centersCollaboration enables rapid deployment of Galapagos' decentralized CAR-T platform across the U.S., improving patient access to potentially life-saving CAR-T treatmentsImportant milestone for Galapagos' U.S. expansion strategy, supporting upcoming pivotal trials and potential future commercial manufacturing of CAR-T therapiesComplement
- Globe Newswire
Galapagos reports first quarter 2024 financial results
Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with BridGene Biosciences and Thermo Fisher Scientific, and investment in Frontier MedicinesTransferred Jyseleca® business to Alfasigma S.p.A., freeing up resources to invest in growth areasGroup net revenues in the first quarter of €100 millionCash and current financial investments of €3.6 billion on 31 March 202
